Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Non-small Cell Lung Cancer (NSCLC) × efatutazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 4 Carcinoma, Non-Small-Cell Lung 3 Thyroid Carcinoma, Anaplastic 2 Respiratory Tract Neoplasms 2 Colorectal Neoplasms 2 Thyroid Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma 1 Liposarcoma 1 Advanced Non-small Cell Lung Cancer (NSCLC) 1 Advanced Cancer 1

Interventions

efatutazone 1 Nivolumab 1 Erlotinib Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01101334 2020-06-16

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Completed

90 enrolled 11 charts

Advanced Non-small Cell Lung Cancer (NSCLC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡